183 related articles for article (PubMed ID: 26270821)
1. Passive Immunization in JNPL3 Transgenic Mice Using an Array of Phospho-Tau Specific Antibodies.
d'Abramo C; Acker CM; Jimenez H; Davies P
PLoS One; 2015; 10(8):e0135774. PubMed ID: 26270821
[TBL] [Abstract][Full Text] [Related]
2. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain.
Boutajangout A; Ingadottir J; Davies P; Sigurdsson EM
J Neurochem; 2011 Aug; 118(4):658-67. PubMed ID: 21644996
[TBL] [Abstract][Full Text] [Related]
3. Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice.
Vitale F; Giliberto L; Ruiz S; Steslow K; Marambaud P; d'Abramo C
Acta Neuropathol Commun; 2018 Aug; 6(1):82. PubMed ID: 30134961
[TBL] [Abstract][Full Text] [Related]
4. Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity.
d'Abramo C; Acker CM; Jimenez HT; Davies P
PLoS One; 2013; 8(4):e62402. PubMed ID: 23638068
[TBL] [Abstract][Full Text] [Related]
5. Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice.
Liu W; Zhao L; Blackman B; Parmar M; Wong MY; Woo T; Yu F; Chiuchiolo MJ; Sondhi D; Kaminsky SM; Crystal RG; Paul SM
J Neurosci; 2016 Dec; 36(49):12425-12435. PubMed ID: 27927959
[TBL] [Abstract][Full Text] [Related]
6. Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice.
Ittner A; Bertz J; Suh LS; Stevens CH; Götz J; Ittner LM
J Neurochem; 2015 Jan; 132(1):135-45. PubMed ID: 25041093
[TBL] [Abstract][Full Text] [Related]
7. Detecting tau in serum of transgenic animal models after tau immunotherapy treatment.
d'Abramo C; Acker CM; Schachter JB; Terracina G; Wang X; Forest SK; Davies P
Neurobiol Aging; 2016 Jan; 37():58-65. PubMed ID: 26508157
[TBL] [Abstract][Full Text] [Related]
8. Small molecule inhibitor of tau self-association in a mouse model of tauopathy: A preventive study in P301L tau JNPL3 mice.
Davidowitz EJ; Lopez P; Jimenez H; Adrien L; Davies P; Moe JG
PLoS One; 2023; 18(8):e0286523. PubMed ID: 37556474
[TBL] [Abstract][Full Text] [Related]
9. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression.
Chai X; Wu S; Murray TK; Kinley R; Cella CV; Sims H; Buckner N; Hanmer J; Davies P; O'Neill MJ; Hutton ML; Citron M
J Biol Chem; 2011 Sep; 286(39):34457-67. PubMed ID: 21841002
[TBL] [Abstract][Full Text] [Related]
10. Tau antibody isotype induces differential effects following passive immunisation of tau transgenic mice.
Bajracharya R; Brici D; Bodea LG; Janowicz PW; Götz J; Nisbet RM
Acta Neuropathol Commun; 2021 Mar; 9(1):42. PubMed ID: 33712083
[TBL] [Abstract][Full Text] [Related]
11. Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model.
Nisbet RM; Van der Jeugd A; Leinenga G; Evans HT; Janowicz PW; Götz J
Brain; 2017 May; 140(5):1220-1230. PubMed ID: 28379300
[TBL] [Abstract][Full Text] [Related]
12. Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis.
Selenica ML; Davtyan H; Housley SB; Blair LJ; Gillies A; Nordhues BA; Zhang B; Liu J; Gestwicki JE; Lee DC; Gordon MN; Morgan D; Dickey CA
J Neuroinflammation; 2014 Sep; 11():152. PubMed ID: 25183004
[TBL] [Abstract][Full Text] [Related]
13. Tau passive immunization inhibits not only tau but also Aβ pathology.
Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
[TBL] [Abstract][Full Text] [Related]
14. [Passive Tau immunotherapy for prevention of Tau pathology progression].
Ozmen L; Collin L
Med Sci (Paris); 2015 Feb; 31(2):132-4. PubMed ID: 25744257
[No Abstract] [Full Text] [Related]
15. Passive Immunotherapy Targeting Tau Oligomeric Strains Reverses Tauopathy Phenotypes in Aged Human-Tau Mice in a Mouse Model-Specific Manner.
Bittar A; Al-Lahham R; Bhatt N; Moore K; Montalbano M; Jerez C; Fung L; McAllen S; Ellsworth A; Kayed R
J Alzheimers Dis; 2022; 90(3):1103-1122. PubMed ID: 36189593
[TBL] [Abstract][Full Text] [Related]
16. Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 × Tg-AD mice.
Dai CL; Hu W; Tung YC; Liu F; Gong CX; Iqbal K
Alzheimers Res Ther; 2018 Jan; 10(1):13. PubMed ID: 29386065
[TBL] [Abstract][Full Text] [Related]
17. Accelerated neurodegeneration and neuroinflammation in transgenic mice expressing P301L tau mutant and tau-tubulin kinase 1.
Asai H; Ikezu S; Woodbury ME; Yonemoto GM; Cui L; Ikezu T
Am J Pathol; 2014 Mar; 184(3):808-18. PubMed ID: 24418258
[TBL] [Abstract][Full Text] [Related]
18. Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds.
Castillo-Carranza DL; Gerson JE; Sengupta U; Guerrero-Muñoz MJ; Lasagna-Reeves CA; Kayed R
J Alzheimers Dis; 2014; 40 Suppl 1():S97-S111. PubMed ID: 24603946
[TBL] [Abstract][Full Text] [Related]
19. Novel Phospho-Tau Monoclonal Antibody Generated Using a Liposomal Vaccine, with Enhanced Recognition of a Conformational Tauopathy Epitope.
Theunis C; Adolfsson O; Crespo-Biel N; Piorkowska K; Pihlgren M; Hickman DT; Gafner V; Borghgraef P; Devijver H; Pfeifer A; Van Leuven F; Muhs A
J Alzheimers Dis; 2017; 56(2):585-599. PubMed ID: 28035925
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylated p38MAPK specific antibodies cross-react with sarkosyl-insoluble hyperphosphorylated tau proteins.
Sahara N; Vega IE; Ishizawa T; Lewis J; McGowan E; Hutton M; Dickson D; Yen SH
J Neurochem; 2004 Aug; 90(4):829-38. PubMed ID: 15287888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]